{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:46:52Z","timestamp":1780465612807,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijbiomac.2026.151043","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T23:04:13Z","timestamp":1771801453000},"page":"151043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A self-assembling ferritin nanoparticle-based trivalent vaccine of gB\/gE\/gH elicits potent immune responses against varicella-zoster virus"],"prefix":"10.1016","volume":"351","author":[{"given":"Jieyi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiantao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151043_bb0005","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrmicro3215","article-title":"Molecular mechanisms of varicella zoster virus pathogenesis","volume":"12","author":"Zerboni","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.151043_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146239940500966X","article-title":"Molecular and therapeutic aspects of varicella\u2013zoster virus infection","volume":"7","author":"Quinlivan","year":"2005","journal-title":"Expert Rev. Mol. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0015","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jmv.27538","article-title":"The global disease burden of varicella-zoster virus infection from 1990 to 2019","volume":"94","author":"Huang","year":"2022","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151043_bb0020","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0025","series-title":"Varicella and Herpes Zoster Vaccines: WHO Position Paper, June 2014, Weekly Epidemiological Record= Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire","first-page":"265","volume":"89(25)","author":"O. World Health","year":"2014"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.151043_bb0030","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0035","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151043_bb0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151043_bb0045","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01816-24","article-title":"Insights into pathologic mechanisms occurring during serious adverse events following live zoster vaccination","volume":"99","author":"Kennedy","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0050","series-title":"Therapeutic Advances in Vaccines and Immunotherapy","article-title":"Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance","volume":"9","author":"Fiore","year":"2021"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151043_bb0055","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vaccine.2020.10.029","article-title":"Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients","volume":"39","author":"Ocran-Appiah","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151043_bb0065","article-title":"Safety of adjuvanted recombinant herpes zoster virus vaccination in fragile populations: an observational real-life study","volume":"12","author":"Costantino","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.151043_bb0070","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Tavares-Da-Silva","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121825","article-title":"Development of (inhalable) dry powder formulations of AS01(B)-containing vaccines using thin-film freeze-drying","volume":"622","author":"AboulFotouh","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151043_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MCP.0b013e3282f79651","article-title":"Respiratory syncytial virus infection in adults","volume":"14","author":"Murata","year":"2008","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151043_bb0085","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1128\/JVI.02592-07","article-title":"Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia","volume":"82","author":"Reichelt","year":"2008","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0090","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1042\/BST20190511","article-title":"Varicella-zoster virus: molecular controls of cell fusion-dependent pathogenesis","volume":"48","author":"Oliver","year":"2020","journal-title":"Biochem. Soc. Trans."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.151043_bb0095","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1128\/JVI.00435-11","article-title":"Neutralizing anti-gH antibody of varicella-zoster virus modulates distribution of gH and induces gene regulation, mimicking latency","volume":"85","author":"Shiraki","year":"2011","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151043_bb0100","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1073\/pnas.1501176112","article-title":"A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL","volume":"112","author":"Xing","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008961","article-title":"The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion","volume":"17","author":"Oliver","year":"2021","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0110","article-title":"A glycoprotein B-neutralizing antibody structure at 2.8\u00c5 uncovers a critical domain for herpesvirus fusion initiation","volume":"11","author":"Oliver","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151043_bb0115","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/jvi.61.9.2877-2884.1987","article-title":"Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140)","volume":"61","author":"Montalvo","year":"1987","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151043_bb0120","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1006\/viro.1994.1145","article-title":"Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex","volume":"199","author":"Forghani","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/9125048","article-title":"Effect of chitosan and liposome nanoparticles as adjuvant codelivery on the immunoglobulin G subclass distribution in a mouse model","volume":"2017","author":"Haryono","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151043_bb0130","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151043_bb0135","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize epstein-barr virus in B cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151043_bb0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.chembiol.2022.02.004","article-title":"Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo","volume":"29","author":"Georgiev","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0145","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","article-title":"Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses","volume":"53","author":"Ma","year":"2020","journal-title":"Immunity"},{"issue":"643","key":"10.1016\/j.ijbiomac.2026.151043_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf3685","article-title":"A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice","volume":"14","author":"Wei","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"7456","key":"10.1016\/j.ijbiomac.2026.151043_bb0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.151043_bb0160","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.21769\/BioProtoc.1295","article-title":"Infectious focus assays and multiplicity of infection (MOI) calculations for alpha-herpesviruses","volume":"4","author":"Sloutskin","year":"2014","journal-title":"Bio-protocol"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.151043_bb0165","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1128\/JVI.01280-12","article-title":"Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein","volume":"86","author":"Inoue","year":"2012","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151043_bb0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/vaccines9040310","article-title":"Immunogenicity of varicella-zoster virus glycoprotein E formulated with lipid nanoparticles and nucleic immunostimulators in mice","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151043_bb0175","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41423-021-00736-2","article-title":"Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151043_bb0180","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41590-024-01776-2","article-title":"The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis","volume":"25","author":"He","year":"2024","journal-title":"Nat. Immunol."},{"issue":"27","key":"10.1016\/j.ijbiomac.2026.151043_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202301034","article-title":"A mosaic nanoparticle vaccine elicits potent mucosal immune response with significant cross-protection activity against multiple SARS-CoV-2 sublineages","volume":"10","author":"Zhang","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0190","article-title":"Development of a skin- and neuro-attenuated live vaccine for varicella","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151043_bb0195","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1007\/s00253-015-6602-5","article-title":"A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine","volume":"99","author":"Liu","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0200","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jmv.20838","article-title":"isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity","volume":"79","author":"Suzuki","year":"2007","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151043_bb0205","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/s41423-021-00736-2","article-title":"Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0210","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1128\/JVI.78.6.2884-2896.2004","article-title":"Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE","volume":"78","author":"Pasieka","year":"2004","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0215","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vaccine.2020.10.029","article-title":"Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients","volume":"39","author":"Ocran-Appiah","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0220","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3390\/molecules27092716","article-title":"Potential of ferritin-based platforms for tumor immunotherapy","author":"Xu","year":"2022","journal-title":"Molecules"},{"issue":"6427","key":"10.1016\/j.ijbiomac.2026.151043_bb0225","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1126\/science.aat9120","article-title":"Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers","volume":"363","author":"Tokatlian","year":"2019","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0230","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on <i>In Vivo<\/i> pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151043_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110256","article-title":"A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2","volume":"38","author":"Yuan","year":"2022","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151043_bb0240","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.ijbiomac.2026.151043_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba6466","article-title":"A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain","volume":"5","author":"Swanson","year":"2020","journal-title":"Sci. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151043_bb0250","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00930-21","article-title":"An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines","volume":"12","author":"Guo","year":"2021","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/JVI.00913-08","article-title":"Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry","volume":"83","author":"Berarducci","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0260","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/vaccines12101111","article-title":"Structures of the Varicella Zoster Virus Glycoprotein E and epitope mapping of vaccine-elicited antibodies","author":"Harshbarger","year":"2024","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0265","doi-asserted-by":"crossref","first-page":"7958","DOI":"10.1038\/s41467-023-43011-w","article-title":"Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49546-w","article-title":"A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection","volume":"15","author":"Zhong","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006141","article-title":"An HSV-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog."},{"issue":"39","key":"10.1016\/j.ijbiomac.2026.151043_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0285","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/s41590-023-01510-4","article-title":"CD4+ T cell memory","volume":"24","author":"K\u00fcnzli","year":"2023","journal-title":"Nat. Immunol."},{"issue":"36","key":"10.1016\/j.ijbiomac.2026.151043_bb0290","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151043_bb0295","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","article-title":"Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial","volume":"28","author":"Houser","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0300","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum adjuvants\u2014\u2018back to the future\u2019","author":"Laera","year":"2023","journal-title":"Pharmaceutics"},{"issue":"Suppl. 2","key":"10.1016\/j.ijbiomac.2026.151043_bb0305","article-title":"Vaccine safety issues at the turn of the 21st century","volume":"6","author":"Conklin","year":"2021","journal-title":"BMJ Glob. Health"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151043_bb0310","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/10408444.2022.2105688","article-title":"Clearance, biodistribution, and neuromodulatory effects of aluminum-based adjuvants. Systematic review and meta-analysis: what do we learn from animal studies?","volume":"52","author":"Masson","year":"2022","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0315","first-page":"406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151043_bb0320","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/mpat.1993.1064","article-title":"A mouse model for varicella-zoster virus latency","volume":"15","author":"Wroblewska","year":"1993","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0325","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.virol.2015.03.046","article-title":"Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia","volume":"482","author":"Guedon","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0330","first-page":"135","article-title":"Humanized severe combined immunodeficient (SCID) mouse models for varicella-zoster virus pathogenesis","volume":"438","author":"Lloyd","year":"2023","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151043_bb0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/viro.2001.0912","article-title":"The DNA sequence of the simian varicella virus genome","volume":"284","author":"Gray","year":"2001","journal-title":"Virology"},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151043_bb0340","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1128\/JVI.01324-15","article-title":"Simian varicella virus is present in macrophages, dendritic cells, and T cells in lymph nodes of rhesus macaques after experimental reactivation","volume":"89","author":"Traina-Dorge","year":"2015","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151043_bb0345","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/13550284.2010.513031","article-title":"Latent simian varicella virus reactivates in monkeys treated with tacrolimus with or without exposure to irradiation","volume":"16","author":"Mahalingam","year":"2010","journal-title":"J. Neurovirol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151043_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101621","article-title":"Functionalizing ferritin nanoparticles for vaccine development","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2026.151043_bb0355","series-title":"Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection","year":"2020"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026009694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026009694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:19:12Z","timestamp":1779164352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026009694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":71,"alternative-id":["S0141813026009694"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151043","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A self-assembling ferritin nanoparticle-based trivalent vaccine of gB\/gE\/gH elicits potent immune responses against varicella-zoster virus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151043"}}